{"analyses":[{"groupDescription":"Treatment comparison between the pexidartinib and placebo groups at Week 25","groupIds":["OG000","OG001"],"nonInferiorityComment":"Treatment comparison analysis","nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"Mixed effects model for repeated measure"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.2","value":"5.6"},{"groupId":"OG001","spread":"0.3","value":"5.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.3","value":"-1.5"},{"groupId":"OG001","spread":"0.3","value":"-0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"title":"Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.3","value":"-2.4"},{"groupId":"OG001","spread":"0.3","value":"-0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"title":"Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.3","value":"-2.5"},{"groupId":"OG001","spread":"0.3","value":"-0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"title":"Week 25"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"description":"The Worst Stiffness Numeric Rating Scale (NRS) was a 1-item, self-administered questionnaire assessing the \"worst\" stiffness in the last 24 hours. The NRS for this item ranged from 0 (no stiffness) to 10 (stiffness as bad as you can imagine).","dispersionType":"Standard Error","groups":[{"description":"Participants received treatment of Pexidartinib,1000 mg (5 capsules per day ) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks Pexidartinib: Each capsule contains 200 mg of Pexidartinib for oral administration.","id":"OG000","title":"Pexidartinib Part 1"},{"description":"Participants received treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks Placebo: Placebo capsule matching Pexidartinib capsule for oral administration.","id":"OG001","title":"Placebo Part 1"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Worst stiffness was assessed in the ITT population.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 9, Week 17, and Week 25","title":"Mean Change From Baseline for Worst Stiffness Numeric Rating Scale Score (NRS) in Participants Receiving Pexidartinib Compared With Those on Placebo Up to Week 25","type":"SECONDARY","unitOfMeasure":"units on a scale"}